274 related articles for article (PubMed ID: 38049825)
1. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
Zhu S; Zhao Q; Fan Y; Tang C
BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
[TBL] [Abstract][Full Text] [Related]
2. A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma.
Chen Z; Liu X; Zhu Z; Chen J; Wang C; Chen X; Zhu S; Zhang A
Front Genet; 2022; 13():1039465. PubMed ID: 36338978
[No Abstract] [Full Text] [Related]
3. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
Song Z; Gui S; Xiao S; Rao X; Cong N; Deng H; Yu Z; Zeng T
Sci Rep; 2024 Feb; 14(1):3198. PubMed ID: 38332160
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
5. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
6. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
9. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
10. An anoikis-based gene signature for predicting prognosis in malignant pleural mesothelioma and revealing immune infiltration.
Shi J; Peng B; Zhou X; Wang C; Xu R; Lu T; Chang X; Shen Z; Wang K; Xu C; Zhang L
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12089-12102. PubMed ID: 37421452
[TBL] [Abstract][Full Text] [Related]
11. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
12. A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma.
Zhang X; Wen Z; Wang Q; Ren L; Zhao S
Front Immunol; 2023; 14():1199869. PubMed ID: 37575253
[TBL] [Abstract][Full Text] [Related]
13. Wnt pathway-related three-mRNA clinical outcome signature in bladder urothelial carcinoma: computational biology and experimental analyses.
Sun S; Wang Y; Wang J; Bi J
J Transl Med; 2021 Sep; 19(1):409. PubMed ID: 34579753
[TBL] [Abstract][Full Text] [Related]
14. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
Xing P; Jiang Z; Liu Y
BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
[TBL] [Abstract][Full Text] [Related]
15. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
Wang H; Liu J; Tang R; Hu J; Liu M; Wang J; Zhang J; Hou H
Eur J Med Res; 2024 Jan; 29(1):52. PubMed ID: 38217031
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
19. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
Hu J; Wang L; Li L; Wang Y; Bi J
BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]